Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.

Ambrosini V, Quarta C, Zinzani PL, Nanni C, Fini M, Torricelli P, Giavaresi G, D'Errico-Grigioni A, Malvi D, Franchi R, Fanti S.

Q J Nucl Med Mol Imaging. 2010 Dec;54(6):689-97. Epub 2010 Jul 16.


High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS.

J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220.


FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.

Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS.

Int J Oncol. 2011 Jul;39(1):91-100. doi: 10.3892/ijo.2011.1019. Epub 2011 Apr 29.


Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.

Lyrdal D, Boijsen M, Suurk├╝la M, Lundstam S, Stierner U.

Nucl Med Commun. 2009 Jul;30(7):519-24.


Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, Bottos A, Gammaitoni L, Migliardi G, Camussi G, Alberghini M, Torchio B, Ferrari S, Bussolino F, Fagioli F, Picci P, Aglietta M.

Mol Cancer. 2009 Dec 10;8:118. doi: 10.1186/1476-4598-8-118.


Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.

Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S.

Liver Int. 2012 Apr;32(4):574-81. doi: 10.1111/j.1478-3231.2011.02729.x. Epub 2011 Dec 18.


18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.

Siemerink EJ, Mulder NH, Brouwers AH, Hospers GA.

Oncologist. 2008 Jun;13(6):734-5; author reply 736-7. doi: 10.1634/theoncologist.2008-0063. No abstract available.


Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S.

Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74. Epub 2006 Dec 8.


Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.

Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1126-33. doi: 10.1002/pbc.22712.


Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.

Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, Radzioch D, Muanza T.

Anticancer Drugs. 2012 Jun;23(5):525-33. doi: 10.1097/CAD.0b013e32834ea5b3.


Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z.

Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.


Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.

Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A.

Oncologist. 2007 Feb;12(2):191-200.


Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Beljanski V, Lewis CS, Smith CD.

Cancer Biol Ther. 2011 Mar 1;11(5):524-34. Epub 2011 Mar 1.


Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, Padussis J, Pruitt SK, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2010 Jul;9(7):2090-101. doi: 10.1158/1535-7163.MCT-10-0073. Epub 2010 Jun 22.


Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.

So BJ, Bekaii-Saab T, Bloomston MA, Patel T.

J Hematol Oncol. 2008 Oct 17;1:18. doi: 10.1186/1756-8722-1-18.


Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.

Tseng JC, Narayanan N, Ho G, Groves K, Delaney J, Bao B, Zhang J, Morin J, Kossodo S, Rajopadhye M, Peterson JD.

PLoS One. 2017 Aug 8;12(8):e0182689. doi: 10.1371/journal.pone.0182689. eCollection 2017.


Sorafenib in hepatocellular carcinoma.

Josephs DH, Ross PJ.

Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. Review.



Hasskarl J.

Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5. Review.


18F-FDG small animal PET for early detection of human anaplastic large cells lymphoma xenograft in immunocompromised mice.

Ambrosini V, Quarta C, Zinzani PL, Fini M, Giavaresi G, Torricelli P, Malvi D, Nanni C, Grassetto G, Rubello D, Fanti S.

Anticancer Res. 2008 Mar-Apr;28(2A):981-7.


Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.

Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK.

Nucl Med Commun. 2012 Sep;33(9):967-73. doi: 10.1097/MNM.0b013e3283561837.


Supplemental Content

Support Center